Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, is pleased annoucned that their first shipments of Pliaglis have now been received and the product will be launched by a U.S. licensing partner.
In April 2017, Crescita entered into a development and commercialization license agreement (“the Agreement”) with Taro Pharmaceuticals Inc.. Under the terms of the Agreement, Crescita granted Taro an exclusive license to the rights to sell and distribute Pliaglis in the U.S. market and for a second-generation enhanced version with patent pending (the Enhanced Formulation).
About Pliaglis
Pliaglis, a lidocaine and tetracaine (seven percent/seven percent) formulation, an FDA approved topical local anesthetic cream that provides safe and effective local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal. This product contains lidocaine and tetracaine and utilizes the proprietary phase-changing topical cream “Peel” technology. The “Peel” technology consists of a drug containing cream which, once applied to a patient’s skin, dries to form a pliable layer that releases drug into the skin. Following the application period, Pliaglis forms a pliable layer that is removed from the skin allowing the dermatological procedure to be performed with minimal to no pain.
(Source: Crescita Therapuetics Inc.)
